Adlai Nortye Group Ltd. ANL
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
Adlai Nortye Group Ltd. (ANL) is a healthcare company listed in the US with a market value of about $683M. In the twelve months to June 30, 2026 it had revenue of $18M and net income of -$23M, a net margin of -124.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -68%.
About Adlai Nortye Group
Adlai Nortye Group is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2023. Revenue went from $46M in 2021 to $5M in 2025, a decline of about 42.5% a year. It was profitable in 0 of the last 5 years in our data. Its share count fell by 50% over three years (buybacks).
Score: 0.6 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $18M | $5M | — | $5M | — | $46M |
| Net income | -$23M | -$36M | -$52M | -$109M | -$59M | -$57M |
| Free cash flow | -$34M | -$34M | -$52M | -$57M | -$44M | -$4M |
| EPS (diluted) | $-0.66 | $-0.56 | $-0.40 | $-0.85 | $-0.46 | $-0.44 |
| Net margin | -124.8% | -710.6% | — | -2184.6% | — | -124.0% |
| ROIC | — | — | -80.7% | -54.4% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $29.50, 178% above the current price; targets range from $20.00 to $49.00; the consensus rating is “Strong buy”; expected EPS is $-0.18 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Adlai Nortye Group pay a dividend?
Not currently.
Is Adlai Nortye Group a good stock to buy?
We do not give buy or sell advice. Adlai Nortye Group scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.